Zydus Cadila has received the final approval from the USFDA to market Arsenic Trioxide Injection, 10 mg/10 mL (1 mg/mL) single-dose vial (US RLD-TRISENOX). It will be manufactured at Alidac Pharmaceuticals, the company's wholly-owned subsidiary located at SEZ, Ahmedabad.

Arsenic Trioxide is used to treat a type of leukemia (acute promyelocytic leukemia-APL) when other types of treatment (e.g., chemotherapy) have not worked well or no longer work.

The group now has 228 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company declined Rs 3.65, or 0.99%, to trade at Rs 366.60. The total volume of shares traded was 9,160 at the BSE (9.59 a.m., Thursday).